JOHNSON & JOHNSON

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. and E.U. DEVELOPMENT OR REGISTRATION

As of July 17, 2012*

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and	XARELTO® (rivaroxaban)	VTE treatment (2)	Filed 5/12	
		Acute Coronary Syndrome (2)	FDA Complete Response Letter 6/12	
	canagliflozin	Type 2 diabetes (2)	Filed 5/12	Filed 6/12
		Fixed Dose Combination with Metformin (2)	Phase III	Phase III
Immunology	STELARA® (ustekinumab)	Psoriatic Arthritis	Phase III	Phase III
		Crohn's Disease	Phase III	Phase III
	SIMPONI® (golimumab)	Rheumatoid Arthritis (IV)	Phase III	Filed 11/11
		Structural Damage (RA)	FDA Complete Response letter 7/11	Approved 1/11
		Structural Damage (PsA)	FDA Complete Response letter 9/11	Approved 5/11
		Ulcerative Colitis	Filed 7/12	Filed 7/12
Infectious Diseases and Vaccines	bedaquiline (TMC 207)	Multi-drug resistant tuberculosis (2)	Filed 6/12	
	DORIBAX™ (doripenem)	Nosocomial Pneumonia (2)	FDA Complete Response letter 8/08 FDA Second Complete Response 10/10	Approved 7/08
	PREZISTA® (darunavir)	HIV 800 mg tablet for treatment naïve patients and treatment experienced patients	FDA Complete Response letter 5/12; Submitted Response to FDA 7/12	Filed 1/12
	TMC435	Chronic hepatitis C virus (HCV) infection for treatment naïve patients and relapsers (2)	Phase III	Phase III
		Chronic hepatitis C virus (HCV) infection for treatment experienced patients and relapsers (2)	Phase III	Phase III
Neuroscience	NUCYNTA® ER (tapentadol)	Diabetic peripheral neuropathy (Extended Release formulation) (2)	Filed 10/11	
	INVEGA® (paliperidone ER OROS)	Pediatric indication - adolescent schizophrenia	Approved 4/11	Phase III
	INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate IM long acting injectable)	Schizophrenia - 3 month injectable (2)	Phase III	Phase III
	bapineuzumab	Mild to moderate Alzheimer's disease (3)	Phase III	
Oncology	ibrutinib (PCI-32765)	Relapsed/refractory patients with Chronic Lymphocytic Leukemia (2)	Phase III	Phase III
	PROCRIT® (epoetin alfa)	Chronic Renal Function - extended dosing (2)	Supplemental application withdrawn 1/12	Filed 4/10
	VELCADE® (bortezomib)	Non-Hodgkin's Lymphoma (2)		Application withdrawn 7/12
		Mantle Cell Lymphoma 1st line (2)		Phase III
		Subcutaneous formulation (2)		Positive CHMP Opinion 6/12
	YONDELIS® (trabectedin)	Soft Tissue Sarcoma (2)	Phase III	
	ZYTIGA® (abiraterone acetate)	Prostate cancer chemo naïve	Filed 6/12	Filed 6/12
	DACOGEN® (decitabine) for Injection	Acute Myeloid Leukemia (2)		Filed 5/11

*** This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.**

(2) Doribax™ developed in collaboration with Shionogi & Co., canagliflozin licensed from Mitsubishi Tanabe Pharma Corporation; Procit®/Eprex® licensed from Amgen Inc., Velcade® developed in collaboration with Millennium Pharmaceuticals, The Takeda Oncology Company,Yondelis® developed in collaboration with PharmaMar, Dacogen® developed in collaboration with Eisai Corporation of North America, Nucynta® co-developed with Grunenthal GMBH, Xarelto® co-developed with Bayer HealthCare, Invega® Sustenna® developed in collaboration with Alkermes, Inc.,TMC435 developed in collaboration with Medivir AB, and ibrutinib developed in collaboration with Pharmacyclics.

(3) bapineuzumab acquired from Elan Pharmaceuticals plc and being developed in collaboration with Pfizer

Johnson & Johnson
Selected Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
Selective Highlights as of July 17, 2012

APPROVED 2011	IN REGISTRATION	PLANNED FILINGS 2012-2015*
EDURANT® (rilpivirine) Infectious Diseases & Vaccines	DACOGEN® (EU) (decitabine) Oncology	Bapineuzumab IV Neuroscience
XARELTO® (US) (Rivaroxaban) Cardiovascular & Metabolism	Canagliflozin Cardiovascular & Metabolism	Fulranumab Neuroscience
INCIVO® (EU) (telaprevir) Infectious Diseases & Vaccines	Bedaquiline (US) (TMC 207) Infectious Diseases & Vaccines	Ibrutinib (PCI-32765) Oncology
ZYTIGA® (abiraterone acetate) Oncology		Siltuximab (CNTO 328) Oncology
NUCYNTA ER® (US) (Tapentadol) Neuroscience		TMC 435 Infectious Diseases & Vaccines

- Filings/approvals assumed to be in US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

Dacogen® developed in collaboration with Eisai Corporation of North America, XARELTO® co-developed with Bayer HealthCare, INCIVO® developed in collaboration with Vertex Pharmaceuticals Incorporated; Fulranumab licensed from Amgen, Inc.; Canagliflozin developed in collaboration with Mitsubishi-Tanabe Pharmaceutical Corporation; TMC435 developed in collaboration with Medivir AB. Bapineuzumab being developed in collaboration with Pfizer; Ibrutinib is being developed in collaboration with Pharmacyclics.

MD&D Pipeline Highlights –Orthopaedics, Diabetes Care, Diagnostics, Infection Prevention/Other, Vision Care

2011/2012 Approved/Cleared

Orthopaedics

COUGAR® LS Lateral Cage

VIPER® LX

EXPEDIUM® LX

RECLAIM™ Hip Revision (EU)

Shoulder Fracture Platform (EU)

AOX Poly for Sigma® and LCS

PINNACLE® CoMplete® Acetabular Hip System (US[2])

TRUMATCH™ (US)

SIGMA® PS150 (EU, Japan)

CERTAS™ Programmable Shunt (US)

GRIPTION TF ™ (TIFOAM) Hip and Knee (EU)

Diabetes Care

ONETOUCH® VERIO ® Blood Glucose System Version 1 (US)

ANIMAS® VIBE™ Insulin Pump and CGM System (CE Mark)

ONETOUCH® VERIO ®IQ Blood Glucose System Version 2.5 (US/EU)

Next Generation POC Testing System (EU)

Diagnostics

VITROS® 4600 System[1]

ORTHO VERSEIA™ Pipetter (US)

ORTHO VERSEIA ™ Pipetter Assays (US[1])

New VITROS® Assay:

- Hepatitis B e-antigen and antibody

-Syphilis (EU)

•Vitamin D (EU)

•Prostate-specific antigen (tPSA & fPSA) (EU)

Infection Prevention/Other

SEDASYS® System (EU)

GLOSAIR™ 600 System (US)[4]

STERRAD® 100NX ® System (Japan)

Pending Approval

Orthopaedics

CAIS Cartilage Regeneration (EU)

Infection Prevention/Other

SEDASYS® System (US[2,5])

Diagnostics

New VITROS® Assays:

•Vitamin D (US)

2012 Planned Submissions

Orthopaedics

Next Generation Knee System

Expedium FAS 2

Diabetes Care

Animas® Vibe™ Insulin Pump and CGM System (PMA[3])

OneTouch® Verio ® Blood Glucose System Version 3

ONETOUCH® Ping® Verio® (US)

Next Generation POC Testing System (Japan

Infection Prevention/Other

Next Gen High-Level Disinfection (EU)

2013+ Planned Submissions

Orthopaedics

New Poly Hip Bearings

Next Generation Hip System

Next Generation Shoulder

CAIS Cartilage Regeneration (US[2])

ReVive ™ SE (US[2])

OV Shoulder

Bone Preserving Hip Stem

DeltaMotion® Hip System (US[2])

Diabetes Care

Next Generation POC Testing System Version 1.5 (EU, Japan)

Next Generation Platform Version 1

Diagnostics

New VITROS® Assays:

-HIV Combo[2]

Next Generation VITROS® System

Transfusion Medicine Platform

CELLEX™ System: Crohn's Disease and Graft-versus-host disease[2]

Rare Sera Assays for ORTHO BioVue® and AutoVue ® (EU notified body review)

Infection Prevention/Other

GLOSAIR™ 600 System (EU[4])

Selective Highlights as of 7/17/012. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Filings/approvals assumed to be U.S. 510K and EU CE Mark unless otherwise noted.

[1] US Regulatory submission based on FDA filing for current platforms

[2] US PMA filing

[3] In collaboration with DexCom. DexCom is PMA holder.

[4] US -GLOSAIR™ Systems released using EPA-cleared Sanosil S010 Solution. EU - GLOSAIR™ 600 System will require EU CE Mark to Machinery Directive. GLOSAIR™ 600 Solution will require registration in each country per local regulatory/registration requirements.

[5] FDA Approvable Letter received 2/12

[6] US NDA filing

MD&D Pipeline Highlights – General Surgery, Specialty Surgery, Cardiovascular Care

2011 /2012 Approved/Cleared

General Surgery

ETHICON SECURE*STRAP*™ 5mm Strap Fixation Device (EU)

DERMABOND™ Advanced

EVERPOINT™ Cardiovascular Needles

PDS™ PLUS Barbed Suture

5mm ENDOPATH® XCEL with OPTIVIEW® Technology

ECHELON™ FLEX Powered ENDOPATH® Stapler 45 & 60 mm (US)

Tissue Approximating Fastener – 5LMS

Percutaneous Surgical Set (US,EU)

Verv® System – NMS technology for OAB (EU)

DERMABOND ™ Mini

Cardiovascular Care

EXOSEAL™ VCD (CE Mark)

THERMOCOOL® SF Irrigated Catheter (US & Japan)

PRESILLION™ Plus Bare Metal Stent (CE Mark)

CARTOSOUND™ (Japan)

EXOSEAL™ VCD (US[1])

CARTO® 3 V2 Navigation Technology (US[2] & CE Mark)

Cardiovascular Care (cont.)

EXOSEAL™ VCD (Japan)

POWERFLEX™ Pro PTA Balloon Next Generation

CARTO® 3 V3 MEM Navigation Technology (US)

THERMOCOOL® SMARTTouch® Contact Force Catheter (CE Mark)

THERMOCOOL® SMARTTouch® Contact Force Catheter (Japan)

SpecialtySurgery

ENSEAL® G2 Super Jaw (US/EU)

EES Generator – HARMONIC® and ENSEAL® Combination Generator (US/EU)

ENSEAL® Next Generation Tissue Sealers (8 product codes) (US, EU)

Acclarent™ – CYCLOPS™ Multi-Angle Endoscope

SURGIFLO® with Integrated Thrombin Kit (EU)

Acclarent™– TULA™ Tube Delivery System (US)

Acclarent ™– TULA™ Iontophoresis System (US)

Acclarent™– SPIN Integrated Balloon Sinuplasty Solution (US)

Acclarent™– *Relieva Ultirra*™ Sinus Balloon Catheter (US)

SURGIFLO® with Integrated Thrombin Kit (US(BLA/PMA))

HARMONIC® Next Gen Lap Shears Platform (US)

Pending Approval

Specialty Surgery

Fibrin Pad (US BLA)[2]

Acclarent – TULA™ Additional Indications

HARMONIC® Next Gen Lap Shears Platform (EU)

Fibrin Pad (EU)

Cardiovascular Care

S.M.A.R.T.®
Stent for SFA (PMA Supp)

nMARQ™ Circular Ablation (CE Mark)

INCRAFT™
AAA Stent Graft (CE Mark)

2012 Planned Submissions

General Surgery

Metabolics

11/12mm ENDOPATH® XCEL with OPTIVIEW® Technology

ETHICON SECURESTRAP™ Open

Ventral Hernia Device

GYNECARE MORCELLEX™ Sigma

Verv® System – NMS technology for OAB (US)

Specialty Surgery

ENSEAL® Next Gen Innovation 1 (US)

ENSEAL® Next Gen Innovation 2 (US/EU)

2013+ Planned Submissions

General Surgery

VICRYL RAPIDE™ Plus Suture

Additional PLUS Barbed Suture

GYNECARE SUI Sling Next Generation

Specialty Surgery

Fibrin Pad (Additional Indications)

MENTOR® Purified Toxin (US BLA)

Cardiovascular Care

THERMOCOOL® SMARTTouch® Contact Force Catheter (US[1])

nMARQ™ Circular Ablation (US[1])

INCRAFT™
AAA Stent Graft (US[2] & Japan)

Renal Denervation Treatment for Hypertension

Selective Highlights as of 7/17/2012. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Filings/approvals assumed to be U.S. 510K and EU CE Mark unless otherwise noted.

[1] US PMA filing

[2] FDA Approvable Letter received 2/12